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In resting conditions brain adenosine concentrations are in nanomolar range, but can 
reach micromolar concentrations in stressful situations such as stroke, 
neurodegenerative diseases or hypoxic regions of brain tumours. Adenosine usually 
produces its cellular effects by activating surface receptors but can also act by reversing 
the reaction catalysed by S-adenosylhomocysteine (SAH) hydrolase, leading to SAH 
accumulation and inhibition of S-adenosylmethionine (SAM)-dependent 
methyltransferases. Astrocytes are essential in maintaining brain homeostasis but their 
pathological activation and uncontrolled proliferation plays a role in neurodegeneration 
and glioma. Adenosine can affect cell proliferation, but the effect of increased adenosine 
concentration on proliferation of astrocytes is not clarified and was addressed in present 
work.  
Human astrocytes (HA) were treated for 3 days with test drugs. 30µM-Adenosine 
caused a 40%±3% (P<0.05, n=5) reduction in cell proliferation/viability, an effect 
reversed by 2U/ml-adenosine deaminase, but unchanged in the presence of 
antagonists of any of the adenosine receptors, suggesting an receptor-independent 
mechanism of action. Adenosine alone did not induce cell death, assessed by lactate 
dehydrogenase release and αII-Spectrin cleavage. 100µM-Homocysteine alone caused 
16%±3% (P<0.05) decrease in HA proliferation. Combined action of adenosine and 
homocysteine decreased  HA proliferation by 76%±4%, an effect higher (P<0.05) than 
the sum of the effect of adenosine and homocysteine alone (56%±5%). The inhibitory 
effect of adenosine on HA proliferation/viability was mimicked by two adenosine 
kinase inhibitors and attenuated in the presence of folate (100µM) or SAM (50-
100µM). The results suggest that adenosine reduces HA proliferation by a receptor-





Adenosine is generated in response to cell stress and cell injury and its concentration 
increases during episodes of hypoxia and inflammation (Lopes et al., 2011), as those 
occurring upon stroke or in brain tumours. Adenosine plays a regulatory role in the 
nervous system by decreasing neurotransmitter release and synaptic transmission, 
including excitatory synaptic transmission (Dunwiddie and Hoffer, 1980; Serpa et al., 
2009; Dias et al., 2013; Pinto et al., 2016), protecting against neurotoxic insults (Ribeiro 
et al., 2003; Serpa et al., 2015) and modulating synaptic plasticity (Santschi et al., 2006; 
Dias et al., 2013). Most of these adenosine actions are mediated by activation of G 
protein-coupled adenosine receptors located at the extracellular membrane, 
specifically A1, A2A, A2B and A3 receptors (Dias et al., 2013; Serpa et al. 2015, 2014). 
However, adenosine may play relevant adenosine receptor-independent functions, 
such as modulation of epigenetic processes (Boison et al., 2013; Williams-Karnesky et 
al., 2013).  
Adenosine can be formed in the extracellular milieu from adenine nucleotides, by the 
action of ecto-nucleotidases, and then enter the cell trough nucleoside transporters, or 
can be formed inside the cell by the action of 5’-nucleotidase, which hydrolyses AMP 
into adenosine, and by the action of the S-adenosylhomocysteine (SAH) hydrolase, 
which converts SAH into adenosine and homocysteine (for review see Fredholm et al., 
2001). SAH is the final product of the S-adenosylmethionine (SAM)-dependent 
methyltransferases-catalysed reactions, in which SAM is the methyl group donor. The 
reaction catalysed by SAH hydrolase is near-equilibrium, so if intracellular levels of 
adenosine or homocysteine increase, SAH levels rise; SAH is a potent inhibitor of SAM-
dependent methyltransferases (for review see Stipanuk, 2004). Intracellular adenosine 
is metabolized by the actions of adenosine kinase (ADK) and adenosine deaminase 
(ADA), which catalyse the phosphorylation and deamination of adenosine into AMP 
and inosine, respectively (Pignataro et al., 2008).  
A recent study has shown that adenosine induces DNA hypomethylation in the brain 
through inhibition of transmethylation reactions (Williams-Karnesky et al., 2013). This 
link between adenosine and methyl group metabolism is relevant since impairment of 
methyl group metabolism is a risk factor for several brain pathologies, including 
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Alzheimer Disease and glioblastoma (Cascalheira et al. 2009, 2015; Semmler et al. 
2006). 
Astrocytes are essential for maintaining brain homeostasis, by supporting neuronal 
development and survival, regulating extracellular ions concentration, uptaking 
neurotransmitters and adenosine, regulating the CNS immune system and modulating 
neurotransmission (see Mederos et al., 2018; Guttenplan and Liddelow, 2018). 
Another role of astrocytes is preservation of tissue integrity after injury, which involves 
their activation into so called reactive astrocytes. Reactive gliosis is characterized by 
phenotypic alterations, increased size and number of astrocytes (Pekny and Nilsson, 
2005). Although astrocytes have all these protective actions, their pathological 
activation and proliferation, may also play a role in neurodegeneration and 
tumorigenesis. Astrocytes in the adult brain do not proliferate and rest in the 
quiescent state of the cell cycle (the G0 phase), unless damage occurs to nerve tissues 
either from trauma or hypoxia as in stroke. In both cases, astrocyte proliferation 
produce glial scar formation by mechanisms still poorly understood (Koyama 2014). In 
other instances abnormal astrocyte proliferation may derange in the growth of 
astrocytomas, such as glioblastoma, or support migration and invasion of brain 
tumours (Matias et al. 2018). It is thus of outmost importance to deeply understand 
the regulation of the astrocyte cell cycle. 
In stressful conditions, found in brain injury, after stroke, in neurodegenerative 
diseases or in hypoxic regions of brain tumours, adenosine can reach micromolar 
concentrations (Latini et al., 1999; Fredholm et al., 2001). These elevated 
concentrations of adenosine modulate astrocyte functions. Previous reports have 
shown that adenosine, by activating adenosine A2A receptors, increases reactive gliosis, 
while activation of adenosine A1 receptors decreases it (see Daré et al., 2007; Boison, 
2008 for review). Activation of adenosine receptors also regulates glutamate uptake 
and the release of immune mediators by astrocytes (Daré et al., 2007). However, the 
effect of adenosine in astrocyte proliferation and viability is not fully clarified.  
Previous studies reported conflicting results. In rat mesencephalic astrocyte/neurons 
co-cultures, micromolar adenosine concentrations decreased the number of GFAP 
positive astrocytes while increasing the number of dopaminergic neurons (Michel et al. 
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1999), probably by activating A2B adenosine receptors. On the other hand, Ciccarelli et 
al. (1994), reported an adenosine A1 receptor-mediated decrease in rat astrocyte 
proliferation, while A2 adenosine receptors agonists elicited an increase in astrocyte 
proliferation. However, the possibility of receptor-independent effects of increased 
levels of adenosine on human astrocytes proliferation and apoptosis, is not clarified 
and was investigated in the present work.  
 
2. Materials and Methods. 
2.1. Cells and materials. 
Cerebral cortex human astrocytes (HA; passage one; Ref. 1800) and astrocyte medium 
were purchased from Sciencell. The drugs deoxycoformycin, 8-cyclopentyl-1,3-
dipropylxanthine (DPCPX), 2-(2-Furanyl)-7-(2-phenylethyl)-7H-pyrazolo[4,3-
e][1,2,4]triazolo[1,5-c]pyrimidin-5-amine (SCH 58261), N-(4-Cyanophenyl)-2-[4-
(2,3,6,7-tetrahydro-2,6-dioxo-1,3-dipropyl-1H-purin-8-yl)phenoxy]-acetamide (MRS 
1754), N-[2-(2-Furanyl)-8-propyl-8H-pyrazolo[4,3-e][1,2,4]triazolo[1,5-c]pyrimidin-5-
yl]-N'-(4-methoxyphenyl)urea (MRE 3008F20) and 4-Amino-5-(3-bromophenyl)-7-(6-
morpholinopyridin-3-yl)pyrido[2,3-d]pyrimidine (ABT 702) were purchased from Tocris 
(Bristol, UK). Adenosine deaminase, L-homocysteine, S-(5′-Adenosyl)-L-methionine 
(SAM), folic acid and adenosine were from Sigma. 5-iodotubercidin, the anti-αII-
spectrin mouse monoclonal antibody (1:1000), raised against human αII-spectrin (C-3; 
aa. 2368–2472; RRID: AB_2194351), were from Santa Cruz Biotechnology and the 
horseradish peroxidase (HRP)-conjugated goat anti-mouse secondary antibody was 
from Bio-Rad. 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium bromide (MTT) was 
from VWR. The anti-GAPDH (6C5; RRID: AB_2536381) mouse monoclonal antibody 
(1:5000) was purchased from Thermo Fisher Scientific. Stock solutions of DPCPX (2 
mM), SCH 58261 (5.1 mM), MRS 1754 (5 mM), MRE 3008F20 (50 mM), 5-
iodotubercidin (32 mM), ABT 702 (100 mM) were prepared in dimethyl sulfoxide 
(DMSO) while adenosine (15 mM),  deoxycoformycin (10 µM), SAM (109 mM) and 
homocysteine (370 mM) stock solutions were prepared in water. Stock solution of folic 
acid (113 mM) was prepared in 1M-NaOH. 
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2.2. HA cultures and drugs incubation conditions: 
HA were plated at a 6500 cell/cm2 density, on Poly-L-Lysine (1 mg/ml) coated plates, and 
grown at 37ºC, in a humidified atmosphere of 5% CO2 and 95% atmospheric air, in 
astrocyte medium (AM) consisting of basal medium supplemented with 2% foetal 
bovine serum (FBS), 1% of astrocyte growth supplement (AGS) and 1% of penicillin 
(10,000 units/mL)/streptomycin (10,000 μg/mL) solution (all from ScienCell). For the 
MTT and LDH assays (see below) cells were grown in 96 wells plates, while for cell 
counting and Spectrin breakdown assays cells were grown in 6 wells plates. Two days 
after plating, cells were treated for 3 days with 30µM-adenosine, 100µM-
homocysteine or both. 30µM adenosine concentration was chosen because this 
concentration of adenosine can be reached in pathophysiologic situation like ischemia 
(Latini et al., 1999), while adenosine concentrations higher than 30µM (e.g. Sai et al., 
2006) are not physiological and its use has been criticised (see Ceruti and Abbracchio, 
2013 ). Since adenosine and homocysteine are rapidly metabolised intracellularly (Di 
Iorio et al., 2002; Han et al., 2014), adenosine (30µM final concentration) and 
homocysteine (100µM final concentration) were reapplied every 8h throughout the 3 
days incubation period, accordingly to Han et al. (2014) protocol. In experiments 
where selective adenosine receptor antagonists were used, they were applied to cells 
30 min before the first adenosine application. In some experiments cells were also 
incubated, from the beginning of the 3 days incubation period, in the presence of 
exogenous adenosine deaminase (ADA, 2 U/ml), inhibitors of adenosine kinase (25 
µM-5-idotubercidin or 15 µM-ABT 702), folate (100 µM) or SAM (50-100 µM). When 
present, SAM (50-100 µM final concentration) was reapplied 48h after the first 
application of SAM. When testing the effect of drug(s), a parallel control assay was 
performed, where the same volume of vehicle replaced the volume of drug(s) solution 
added to the well. 
2.3. Cell proliferation and cytotoxicity assays: 
MTT assay: Viability of HA cells was assessed by the metabolism of 3-(4,5-
dimethylthiazol-2-yl)-2,5-diphenyl tetrazolium (MTT)  bromide. After incubation with 
drugs, culture medium was refreshed, MTT (0.5 mg/ml final concentration) was added 
and cells incubated for 3h at 37ºC. After this period, medium was discarded and the 
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formazan crystals, formed from MTT reduction catalysed by cell dehydrogenases, were 
solubilized with dimethyl sulfoxide (DMSO, Merck) and absorbance of the resulting 
solution was measured at 570 nm. The effect of a drug on cell viability was assessed as 
the absorbance at 570 nm corresponding for the drug assay, expressed as the 
percentage of the absorbance at 570 corresponding to the control assay. Since the 
final absorbance at 570 nm increases proportionally with the number of cells present 
in each well, the MTT assay is also an indirect measure of cell proliferation. 
Cell counting: In some experiments cell proliferation was directly evaluated by 
counting cells with a Neubauer chamber. Briefly, after incubation with drugs, cells 
were rinsed with Dulbecco's phosphate-buffered saline (DPBS), and treated with 0.2 ml 
of trypsin/EDTA solution (ScienCell) in 1ml of DPBS for 1-2 min to detach cells. 
Trypsinization was stopped by adding FBS (20% final concentration), cells were 
collected, centrifuged at 1000 rpm for 5min, resuspended in DPBS and counted with a 
Neubauer chamber after adding an equal volume of 0.4% trypan blue dye. In 
experiments were released LDH was quantified, prior to trypsinization of adherent 
cells, the culture medium in each well was collected, centrifuged at 1000 rpm for 5min, 
and non-adherent cells were counted after being resuspended in DPBS. Total cells, 
adherent + non-adherent, were then quantified.  
Cytotoxicity LDH assay: After incubation with drugs, aliquots of culture medium were 
collected to assess lactate dehydrogenase (LDH) activity. LDH activity was measured at 
room temperature using a commercial kit (LDH cytotoxicity assay kit, Cayman 
Chemical, Ann Arbor, USA). Released LDH activity was expressed as µUnits/1000 total 
cells. 
 
2.4. Evaluation of apoptosis by western blot analysis of Spectrin Breakdown: 
As described previously (Jerónimo-Santos et al., 2015), after incubating with drugs, HA 
cells were washed with ice cold DPBS and lysed with lysis buffer containing: 1% NP-40, 
50mM TrisHCl (pH 7.5), 150mM NaCl, 5mM ethylenediamine tetra-acetic acid (EDTA), 
2mM dithiothreitol (DTT) and protease inhibitors cocktail (Roche). Cell lysates were 
centrifuged (16,000 g, 10 min) and the protein concentration in the supernatant was 
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measured by Bio-Rad DC reagent. All Samples (30µg of total protein) were separated 
on 12% sodium dodecyl sulphate-polyacrylamide gel electrophoresis (SDS-PAGE) and 
transferred onto PVDF membranes (GE Healthcare). Membranes were stained with 
Ponceau S solution to evaluate for protein transference efficacy. Membranes were first 
blocked with a 3% BSA solution in TBS-T (137 mM NaCl, 20 mM Tris base and 0.1% 
Tween-20; pH 7.5), and then incubated overnight at 4 ºC with the primary antibodies 
(anti-αII-spectrin or GAPDH mouse monoclonal antibodies). Finally, membranes were 
incubated for 1 h at room temperature with the goat anti-mouse IgG secondary 
antibody. Immunoreactivity was visualized using an ECL chemiluminescence detection 
system (Amersham-ECL Western Blotting Detection Reagents from GE Healthcare). 
Bands intensities were quantified using ImageJ 1.45 software. The band intensities 
were normalized to the correspondent GAPDH bands (loading control). Extension of 
activation of cell death pathways in astrocytes was assessed by measuring the αII-
spectrin breakdown, a cytoskeletal protein that is cleaved by both calpains, producing 
an 145 and an 150 kDa spectrin breakdown products (SBDPs), and caspase-3, forming 
an 150 and an 120 kDa SBDPs (see Zhang et al. 2009). The effect of the tested drugs on 
the 120 SBDP/αII-spectrin and 145-150 SBDP/αII-spectrin ratios was evaluated. 
 
2.5. Statistical Analysis: 
The values are expressed as mean ± S.E.M. from n independent cell cultures. Normality 
of data was assessed by the Kolmogorov-Smirnov and Shapiro-Wilk tests. All studied 
variables did not deviate from Normal distribution. The significance of the differences 
between the means obtained in two different conditions, or when comparing means 
with a fixed value, was evaluated by Student's t-test, where the paired Student's t-test 
was used whenever evaluating the significance of differences between two conditions 
tested in a paired way in the same experiment. When more than two different 
conditions were simultaneously considered, the one-way or two-way (when two factor 
were analysed) ANOVA were used, followed by the Tukey HSD post hoc test. Statistical 
significance was considered for P<0.05. The maximal effect (Emax) and the 
concentration of agonist producing half-Emax (EC50) were calculated by fitting the 
agonist concentration-response curve data to a sigmoidal curve equation, through 
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non-linear regression analysis. Statistical analysis was performed using the SPSS 




3.1. Adenosine decreases astrocyte proliferation/viability independently of receptor 
activation. 
Adenosine (30 µM) when applied for 3 days, caused a 40%±3% decrease on HA cell 
proliferation/viability (n=5; P<0.05 when compared with control, ANOVA followed by 
Tukey HSD test) as assessed by the MTT assay (Fig. 1). We then tested if this adenosine 
effect was receptor-mediated. For that purpose, the effect of Adenosine (30 µM) on 
HA proliferation/viability was assessed in the absence and in the presence of 
adenosine receptors selective antagonists. The following antagonists concentrations 
were used: 15µM for DPCPX, 10µM for SCH 58261, 0.1µM for MRS 1754 and 1.5µM for 
MRE 3008F20; these concentrations are high enough to block effectively the 30µM-
adenosine activation of human A1, A2a, A2b and A3 adenosine receptors, respectively 
(see Fredholm et al., 2001). As shown in Figure 1A, the decrease on HA 
proliferation/viability produced by 30µM-adenosine was not modified by the presence 
of selective antagonist of any of the adenosine receptors, alone or in combination, 
(n=4; P>0.05 when comparing the effect of adenosine alone with the effect of 
adenosine in the presence of any of the antagonists or in the presence of all 
antagonists, ANOVA followed by Tukey HSD test) indicating that the effect of 
adenosine is not receptor-mediated.  
Since adenosine phosphorylation into AMP by the action of ADK is the main route of 
intracellular adenosine removal in astrocytes (see Boison, 2013), we tested if inhibiting 
ADK, and consequently increasing endogenous adenosine intracellular concentration, 
would mimicked the effect of exogenously applied adenosine. Indeed 5-iodotubercidin 
(ITU, 25 µM), a high potency ADK inhibitor, decrease HA proliferation/viability by 
82%±3% (n=3, see fig. 1A). Since ITU, although highly potent at inhibiting ADK, might 
also inhibit other kinases (e.g. Massillon et al., 1994), we also tested the effect of a 
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more selective although less potent ADK inhibitor, ABT 702 (Jarvis et al., 2000), on HA 
proliferation/viability. Performing a concentration-response curve for ABT 702 (0.5-15 
µM), a maximal inhibition of 74%±19% and an EC50 of 12±5µM were obtained. ABT 702 
at a concentration of 15 µM produced a 41%±3% (n=3) inhibition of the HA 
proliferation/viability (see fig. 1A), which was nearly identical to the inhibitory effect 
elicited by 30 µM-adenosine. The observation that inhibition of ADK mimicked the 
inhibitory effect elicited by exogenous adenosine on HA proliferation/viability, also 
indicates that the adenosine effect does not require its phosphorylation into AMP. 
Since the hydrolysis of adenosine into inosine, by the action of ADA, is one of the 
catabolic reactions involved in adenosine metabolism, we investigated if the adenosine 
effect on HA proliferation/viability requires its conversion into inosine. For that 
purpose, the effect of adenosine was assessed in the absence and in the presence of 
exogenously added ADA (2U/ml). As shown in fig. 1B, when present, ADA completely 
reverted the effect 30 µM-adenosine (n=3; P<0.05 when comparing adenosine alone 
with adenosine in the presence of ADA, ANOVA followed by Tukey HSD test), while 
ADA alone did not modify HA proliferation/viability (n=3; P>0.05 when compared with 
control, ANOVA followed by Tukey HSD test). These results indicate that the effect of 
adenosine on HA proliferation/viability is not mediated by its conversion into inosine. 
On the other hand, when we tried to increase endogenous adenosine by inhibiting its 
degradation by endogenous ADA using deoxycoformycin, a potent and selective ADA 
inhibitor, we didn’t observe modification of HA proliferation/viability. The HA 
proliferation/viability obtained in the presence of 1nM-deoxycoformycin – a 
concentration which fully inhibits ADA (Klohs and Kraker, 1992) – was 106%±11% (n=3) 
of the control, which was not significantly different from the control 
proliferation/viability (P>0.05, Student’s t-test). This result suggests that ADA might 
not play a major role on adenosine catabolism in HA, in contrast to ADK (see Boison 
2013). 
 
3.2. The inhibitory effect of adenosine on astrocyte proliferation/viability is potentiated by 
homocysteine and attenuated by methyl-group donors. 
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Since the effect of adenosine on HA proliferation/viability was not adenosine receptor-
mediated, the possibility that the adenosine effect might involve reversal of the near-
equilibrium reaction catalysed by SAH hydrolase, was investigated. The effect of 
adenosine (30 µM) on HA proliferation/viability was assessed in the absence and in the 
presence of homocysteine (100 µM). As shown in fig. 2A, the inhibitory effect of 
combined adenosine and homocysteine on HA proliferation/viability was 76%±4% 
(n=5), which was higher than the sum of the effects of adenosine and homocysteine 
alone (56%±5% inhibition, n=5; P<0.05 when compared with the % inhibition produced 
by combined adenosine and homocysteine, ANOVA followed by Tukey HSD post hoc 
test), indicating a potentiation of the adenosine effect by homocysteine. This result 
suggests that the adenosine effect on HA proliferation/viability involves its 
combination with homocysteine to produce SAH, a reaction catalysed by SAH 
hydrolase; since this reaction is near equilibrium (see Stipanuk, 2004) an increase in 
both the adenosine and homocysteine concentrations would produce a multiplicative, 
rather than additive, increase on SAH intracellular concentration.  
If the adenosine inhibition of HA proliferation/viability involves reversal of the SAH 
hydrolase catalysed reaction, leading to SAH accumulation and consequent inhibition 
of SAM-dependent methyltransferases, then it would be expected that increasing 
methyl-group donors concentration would reverse or attenuate the inhibitory effect of 
adenosine. We started by studying the influence of increasing folate concentration on 
the inhibitory effect of adenosine on HA proliferation/viability. In the cell, folate can be 
converted to N5-methyltetrahydrofolate, a coenzyme for the methionine synthase, 
leading to an increased remethylation of homocysteine to methionine, the precursor 
of SAM (see Stipanuk, 2004). As shown in fig. 2B, addition of folate (100 µM) produced 
a decrease, from 41.2%±4.8% in the absence to 16%±10% in the presence of added 
folate, of the inhibitory effect of adenosine (30 µM) on HA proliferation/viability 
(P<0.05; ANOVA followed by Tukey post hoc test). In the presence of added folate (100 
µM), adenosine (30 µM) did not significantly modify HA proliferation/viability; added 
folate (100 µM) alone had no effect on HA proliferation/viability (see fig. 2B). In 
another set of experiments, we investigated if increasing SAM concentration, the co-
substrate of methyltransferases, would affect the inhibitory effect of adenosine on HA 
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proliferation/viability. As shown in fig. 2C, the inhibitory effect of adenosine (30 µM) 
on HA proliferation/viability was decreased from 33.2%±4.2%, in the absence, to 
18.2%±4.6% or 17.4%±4.2%, in the presence of respectively 50 µM or 100 µM SAM 
(P<0.05; n=7-8, ANOVA followed by Tukey post hoc test). The HA proliferation/viability 
obtained in the presence of 50 µM or 100 µM SAM alone was 88%±9% or 77%±8% of 
control, respectively, which was not significantly different from the  control HA 
proliferation/viability ( P>0.05; n=7-8, ANOVA followed by Tukey post hoc test). 
 
3.3. Adenosine decreases HA proliferation but does not increase cell death. 
Although adenosine has shown to decrease HA proliferation/viability, as assessed by 
the MTT assay, the above data do not allow to discriminate between an inhibitory 
action of adenosine upon cell proliferation and an enhancement of cell death. To 
answer this question we assessed cell proliferation, by counting the number of cells, 
and cell death, by measuring released LDH activity. In figure 3A are represented the 
number of cells/cm2, obtained after incubating HA for 3 days with adenosine (30 µM), 
homocysteine (100 µM), adenosine plus homocysteine, or the ADK inhibitor ABT 702 
(15 µM). Adenosine, homocysteine and ABT 702 all produced a decrease in the 
number of cells, which was similar to the decrease produced by each of these 
molecules in cell proliferation/viability assessed by the MTT assay (compare fig. 3A 
with fig. 2A). On the other hand, as shown in figure 3B in another set of experiments, 
neither adenosine (30 µM) alone nor the ADK inhibitor ITU (25 µM) affected cell death 
assessed by released LDH activity. However, homocysteine (100 µM) alone produced a 
marked increase in LDH release, which was potentiated by the presence of adenosine 
(fig. 3B). These results suggest that the decrease in cell number produced by adenosine 
alone is consequence of a decrease in cell proliferation, while the decrease on cell 
number produced by homocysteine is due, at least in part, to increased cell death. 
Since LDH release does not discriminate cell death by necrosis or late apoptosis, the 
effect of adenosine (30 µM), homocysteine (100 µM), adenosine plus homocysteine 
and ABT 702 (15 µM) on αII-Spectrin breakdown was investigated in HA cells (Fig. 4). 
Similar to what was observed for LDH release, neither adenosine alone nor the ADK 
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inhibitor ABT 702 modify the SBDP120/αII-Spectrin or the SBDP145-150/αII-Spectrin 
ratios, suggesting that increased levels of adenosine did not per se induce HA 
apoptosis or necrosis (Fig. 4B and 4C). Homocysteine, both alone and in the presence 
of adenosine, increased the SBDP120/αII-Spectrin ratio, indicating increased caspase-3 
activation and apoptosis (Fig. 4B). A significant increase in the SBDP145-150/αII-
Spectrin ratio was only observed when homocysteine and adenosine were both 






The present work shows, for the first time, an inhibition of human astrocyte 
proliferation by increased adenosine concentrations that is not mediated by activation 
of adenosine receptors. The effect of adenosine on astrocyte proliferation was 
potentiated by homocysteine and attenuated by the methyl group donors folate and S-
adenosylmethionine. Adenosine alone did not induce cytotoxicity, but potentiated 
homocysteine cytotoxic effect on astrocytes. 
Previous reports of the effect of adenosine on astrocyte proliferation present 
conflicting results. In rat mesencephalic astrocyte/neurons co-cultures, micromolar 
adenosine concentrations decreased the number of GFAP positive astrocytes while 
increasing the number of dopaminergic neurons (Michel et al. 1999), probably by 
activating A2B adenosine receptors. On the other hand, Ciccarelli et al. (1994), reported 
an adenosine A1 receptor-mediated decrease in rat astrocyte proliferation, while A2 
adenosine receptors agonists elicited an increase in astrocyte proliferation. Rathbone 
et al. (1992) also described an adenosine A2 receptor-mediated increase in chick 
astrocytes proliferation. The differences among the results obtained by the different 
groups in these previous reports and between these previous studies and the results 
obtained in the present work, might be due to the use of astrocytes from different 
species and/or different astrocyte culture conditions. Since all previous studies of the 
adenosine effect on astrocyte proliferation only focus on adenosine receptors-
mediated effects, the inhibition of HA proliferation by adenosine described in the 
present work, independent of receptor activation, constitute a novel mechanism by 
which elevated concentrations of adenosine regulate astrocyte proliferation. 
The results obtained in the present study, strongly suggest that adenosine inhibits 
astrocyte proliferation by a receptor-independent mechanism, probably mediated by 
reversal of the SAH hydrolase-catalysed reaction, leading to accumulation of SAH and 
consequent inhibition of SAM-dependent methyltransferases. The proposed 
mechanism is depicted in figure 5. The results which support this conclusion are: 
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i) The effect of adenosine is not modified in the presence of antagonists of any of 
the adenosine receptors, alone or in combination. 
ii) The effect of combined adenosine and homocysteine on astrocyte 
proliferation/viability is higher than the sum of the individual effects of adenosine and 
homocysteine. This suggests that the adenosine effect involves its combination with 
homocysteine to produce SAH, by the action of SAH hydrolase, which catalysed a near 
equilibrium reaction (Stipanuk, 2004), and therefore an increase in both the adenosine 
and homocysteine concentrations would produce a multiplicative increase on SAH 
intracellular concentration, rather than an additive increase which would be the case if 
the effects of both molecules were independent. 
iii) The adenosine-induced inhibition of HA proliferation was attenuated by the 
presence of exogenous folate and SAM. Folate, after being converted to N5-
methyltetrahydrofolate, acts as coenzyme for the methionine synthase, leading to an 
increased remethylation of homocysteine to methionine, the precursor of SAM (see 
Stipanuk, 2004). SAM is the methyl group donor for the methyltransferases-catalysed 
reactions. 
A previous study performed in the RCR-1 rat astrocytoma cell line (Sai et al. 2006), 
reported an adenosine-induced decrease on cell viability by two independent 
mechanisms: activation of adenosine A1 receptors and activation of AMPK after 
intracellular adenosine phosphorylation into AMP by ADK. However the conclusions 
made in this study had been questioned by others (see Ceruti and Abbracchio 2013), 
since Sai et al. (2006) used extremely high adenosine concentrations (1mM) and 
obtained a very low reversal of the adenosine-mediated effect by both A1 receptor 
antagonist (8-CPT) and an ADK inhibitor (AMDA), which leaves the possibility that the 
reported adenosine effect might also involve reversal of SAH hydrolase-catalysed 
reaction. In the present study a 30 µM adenosine concentration was used, since this 
concentration has been reported to be reached under pathophysiological situations 
such as ischemia (Latini et al. 1999; Fredholm et al. 2001). On the other hand, the 
observation in the present study, that two selective ADK inhibitors (5-iodotubercidin 
and ABT 702), in concentrations able to elicit endogenous adenosine intracellular 
accumulation (Boison 2013; Jarvis et al. 2000), mimicked the inhibitory effect of 
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exogenously added adenosine on astrocyte proliferation, indicates that adenosine 
does not requires ADK-catalysed phosphorylation into AMP to produces its inhibitory 
effect on astrocyte proliferation.  
The observation in the present study that adenosine alone did not modify cell death, 
indicates that the decrease in cell number induced by adenosine reflects a decrease in 
cell proliferation rather than an increase in cell death. This contrast to the observed 
effect of homocysteine, which, although produced a much smaller reduction in HA cell 
number than adenosine, was able to increase cell death. Cell death was evaluated by  
measuring released LDH activity – which reflects cell necrosis and late apoptosis 
(Parhamifar et al. 2013) – and increase in αII-Spectrin breakdown – which measures 
both cell apoptosis and necrosis (Zhang et al. 2009). The increase in SBDP120/αII-
Spectrin ratio by homocysteine reflects an increase in caspase 3-mediated apoptosis, 
while the increase in SBDP145-150/αII-Spectrin ratio and in LDH release suggests that 
an increased cell necrosis might also be involved in the homocysteine effect. Curiously, 
the cytotoxic effect of homocysteine in HA was potentiated by adenosine. Although 
both adenosine and homocysteine may decrease HA proliferation by reversal of SAH 
hydrolase-catalysed reaction, the results suggest that part of the effect of 
homocysteine in decreasing HA number involves increased cell death, which is not 
unexpected since increased homocysteine levels also increase oxidative stress (see 
Mattson and Shea 2003). Contrasting with the results obtained in the present study, Di Iorio 
et al. (2002) reported an increase of apoptosis by micromolar adenosine 
concentrations in rat astrocytes, an effect partially mediated by adenosine A3 
receptors and in part mediated by an intracellular mechanism probably involving 
accumulation of SAH and reduction of the SAM/SAH ratio. Again, the difference 
between the results obtained by Di Iorio et al. (2002) and the results obtained in the 
present work, may reflect the use of astrocytes from different species and/or different 
astrocyte culture conditions. 
The inhibition of HA proliferation by adenosine observed in the present study, 
suggests that adenosine may play a relevant role in situations of elevated adenosine 
concentrations, such as in hypoxia, inflammation or brain injury, preventing 
uncontrolled astrocyte proliferation that might occur in neurodegenerative diseases 
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and brain tumours. Receptor-mediated actions of adenosine have been described in 
glioblastoma, the most aggressive astrocyte-derived brain tumour,  but the results are 
conflicting. Activation of A1 and A2B adenosine receptors decreased proliferation and 
induced apoptosis of glioblastoma cancer stem cells (CSC) while in non-CSC 
glioblastoma cell lines activation of either A1, A2B or A3 adenosine receptors increased 
cell proliferation (Daniele et al. 2014; Rathbone et al. 1992). On the other hand, in 
glioblastoma CSC under hypoxic conditions, Liu et al. (2014) reported a pro-
proliferative action of adenosine, trough A2B receptor activation.     
The results obtained in the present study, support the link between adenosine and 
methyl group metabolism, which is relevant since impairment of methyl group 
metabolism is a risk factor for several brain pathologies, including Alzheimer Disease 
and glioblastoma (Cascalheira et al., 2009, 2015; Semmler et al., 2006). Previous 
studies have shown that adenosine can regulate cell functions by interfering with the 
transmethylation pathway. In the brain, adenosine was able to reduced 
epileptogenesis by inducing DNA hypomethylation through inhibition of 
transmethylation reactions (Williams-Karnesky et al., 2013). Adenosine, by increasing 
SAH accumulation and inhibition of SAM-dependent methtyltransferases, was also 
able to induced tumour cells cytotoxicity and DNA hypomethylation in a mouse 
lymphoma cell line (Kredich and Martin, 1977) and induced apoptosis in a hepatoma 
cell line (Hermes et al. 2007; Liu et al. 2016). SAM-dependent methyltransferases 
mediate epigenetic modifications by methylation of DNA, histones, mRNA and tRNA, 
besides regulating catecholamines concentration and phospholipid turnover (Stipanuk, 
2004; Struck et al., 2012). Since these enzymes have such diverse targets, the actual 
mechanism(s) by which adenosine regulate HA proliferation, described in the present 
study, is unknown but deserves future investigation. 
In conclusion, the results obtained in the present study show that increased 
adenosine concentrations inhibit human astrocyte cell proliferation by an adenosine 
receptor-independent mechanism, without affecting cell death providing that 
homocysteine levels stay low. The results also strongly suggest that this effect is a 
consequence of reversal of the near-equilibrium SAH hydrolase-catalysed reaction, and 
subsequent inhibition of SAM-dependent methyltransferases. This study thus opens a 
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Figure 1. Effect of adenosine, adenosine receptors antagonists and adenosine kinase 
inhibitors on human astrocyte proliferation/viability. (A) Cells were incubated for 3 days in 
the presence of vehicle (control) or in the presence of 30µM-adenosine, with or without 
selective adenosine receptor antagonists, or in the presence of 25 µM-5-iodotubercidin (ITU) 
or 15 µM-ABT 702. After this period, medium was replaced by fresh medium and cell 
proliferation/viability was assessed by the MTT assay. The following antagonists were used: 
15µM-DPCPX for A1, 10µM-SCH 58261 for A2a, 0.1µM-MRS 1754 for A2b and 1.5µM-MRE 
3008F20 for A3 adenosine receptors. Results are mean ± SEM of % of control cell 
proliferation/viability of 3-4 independent experiments run in sextuplicate. (B) HA cells were 
incubated for 3 days in the presence of vehicle (control) or in the presence of 30µM-
adenosine, with or without adenosine deaminase (2 U/ml). After this period, medium was 
replaced by fresh medium and cell proliferation/viability was assessed by the MTT assay. 
Results are mean ± SEM of % of control cell proliferation/viability of 3 independent 
experiments run in sextuplicate. ADO- adenosine; Ant. Cocktail – cocktail of all antagonist; 
ADA- adenosine deaminase. (*), (§), (#) Statistically different from control, from the 
corresponding antagonist(s) alone or from adenosine alone, respectively (P<0.05, One-Way 
ANOVA followed by Tukey HSD post hoc test). Individual points are represented by open 
circles. 
 
Figure 2. The inhibitory effect of adenosine on astrocyte proliferation/viability is potentiated 
by homocysteine and attenuated by Folate and SAM. (A) HA cells were incubated for 3 days in 
the presence of vehicle (control) or in the presence of 30 µM-adenosine (ADO), 100 µM-
homocysteine (HCY) or 30 µM-adenosine+100 µM-homocysteine (HCY+ADO). After this period, 
medium was replaced by fresh medium and cell proliferation/viability was assessed by the 
MTT assay. Results are mean ± SEM of % of control cell proliferation/viability of 5 independent 
experiments run in sextuplicate. (B) HA cells were incubated for 3 days in the presence of 
vehicle (control) or in the presence of 30 µM-adenosine (ADO), with or without folate (100 
µM). After this period, medium was replaced by fresh medium and cell proliferation/viability 
was assessed by the MTT assay. Results are mean ± SEM of % of control cell 
proliferation/viability of 4-9 independent experiments run in sextuplicate. (C) Cells were 
incubated for 3 days in the presence of vehicle (control) or in the presence of 30 µM-
adenosine (ADO), with or without S-adenosyl-L-methionine (SAM, 50-100 µM). After this 
period, medium was replaced by fresh medium and cell proliferation/viability was assessed by 
the MTT assay. Results are mean ±SEM of % of control proliferation/viability of 7-8 
30 
 
independent experiments run in sextuplicate; for calculating the effect of adenosine alone the 
control was vehicle while for calculating the effect of adenosine in the presence of SAM (50-
100 µM) the control was SAM (50 -100 µM) alone. ADO/SAM 50 µM, ADO/SAM 100 µM – 
Effect of adenosine on the presence of SAM 50 µM or SAM 100 µM, respectively. (*), (§), (#) 
Statistically different from control (vehicle), from adenosine  or from HCY alone, respectively 
(P<0.05, ANOVA followed by Tukey HSD post hoc test). NS- non-significantly different, P>0.05. 
Individual points are represented by open circles. 
 
Figure 3. Effect of adenosine on cell proliferation and adenosine cytotoxicity in HA. Cells 
were incubated for 3 days in the presence of vehicle (control) or in the presence of 30 µM-
adenosine (ADO), 100 µM-homocysteine (HCY), 30 µM-adenosine+100 µM-homocysteine 
(HCY+ADO) and 15 µM-ABT 702 (A) or 25 µM-5-iodotubercidin (ITU, B). After this period, cells 
and medium were collected for further analysis. (A) Cell proliferation was assessed by cell 
counting. Results are mean ± SEM of % of control cell number of 3-4 independent experiments 
run in quadruplicate. (B) Cell death was evaluated by quantifying the released LDH activity in 
the cell medium. Results are mean ± SEM of released LDH activity per 1000 cells of 3 
independent experiments run in quadruplicate. (*), (§) Statistically different from control or 
from homocysteine alone, respectively (P<0.05, ANOVA followed by Tukey HSD post hoc test). 
Individual points are represented by open circles. 
 
Figure 4. Effect of adenosine on αII-Spectrin breakdown. Cells were incubated for 3 days in 
the presence of vehicle (control) or in the presence of 30 µM-adenosine (ADO), 100 µM-
homocysteine (HCY), 30 µM-adenosine+100 µM-homocysteine (HCY+ADO) or 15 µM-ABT 702 
(ABT). After this period cells were lysed and cell lysates were analysed by Western-Blot using 
an anti-αII-Spectrin antibody. The areas corresponding to αII-Spectrin and to the SBDP120 and 
SBDP145-150 breakdown products were quantified. (A) Representative Wester-blots, showing 
the protein levels of αII-Spectrin, SBDP145-150 and SBDP120 obtained in the different 
conditions. GAPDH was used as loading control. (B) and (C) SBDP120/αII-Spectrin and 
SBDP145-150/αII-Spectrin ratios, respectively, obtained in the different conditions. Results are 
mean ± SEM of % of control SBDP120/αII-Spectrin or SBDP145-150/αII-Spectrin ratios, 
corresponding to 3 independent experiments run in quadruplicate. (*) Statistically different 




Figure 5. Proposed mechanism of adenosine-induced inhibition of human astrocyte 
proliferation. Under increased intracellular concentrations, adenosine combines with 
homocysteine to produce SAH, by reversal of the near-equilibrium SAH hydrolase-catalysed 
reaction, leading to SAH accumulation and consequent inhibition of SAM-dependent 
methyltransferases. Decreased methyltransferases activity would consequently decrease 
astrocyte proliferation. ADA- Adenosine deaminase; ADK- adenosine kinase; SAH- S-
adenosylhomocysteine; ITU- 5-iodotubercidin; MS- methionine synthase; SS- SAM synthetase; 
X- methyltransferase substrate; CH3-X- methylated substrate; N5-MeTHF- N5-
methyltetrahydrofolate. 
